Apr. 24 at 9:41 AM
$NNOX Facts:
1.The technology is real.
2. The product is great. Winning prizes.
3. Sales ramping up. Granted - slow, but happening.
4. Clear interest from the market.
5. Posotive reviews coming from customers.
6. Much cheaper to install than traditional X-ray.
7. Diagnostic power rivaling CT at fraction of radiation dose and fraction of the price.
8. Adjunctive use limitation still depressing sales.
9. Nnox proven track record working with FDA.
10. TAP2D approved - a step towards removal of Adjunctive use limitation.
11. Opex reduced with Korean fab conversion to R&D.
12. CFO leave is orderly. Not abrupt.
13.
$35M 2026 revenue goal reiterated. This is ~2-3X yoy.
14. Multiple distribution contracts being signed.
It's taking longer than I hoped for, but it's moving in the right direction.
2026 is the year of inflection. Starting 2nd half.
